AI assistant
IMUGENE LIMITED — Interim / Quarterly Report 2011
Feb 27, 2011
65124_rns_2011-02-27_ca0c57b6-2c9e-40bc-87ad-d6d9bfe32269.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
==> picture [173 x 63] intentionally omitted <==
ASX ANNOUNCEMENT
Revised 4D
28 February 2011, Sydney, Australia: Imugene (ASX.IMU) releases a revised 4D for the half year ended 31 December 2011.
The revised 4D for the half year ended 31 December 2011 replaces the 4D released on Friday 25 February 2011.
A correction has been made to the percentage change in profit / (loss) when compared to the previous period.
ENDS
About Imugene
Imugene specialises in the development and commercialisation of novel animal health products for pigs and poultry. Our range of products under development includes vaccines to prevent important livestock diseases and productivity enhancers to improve the economics of raising commercial livestock.
Imugene’s biologically based vaccines are safer and easier to use than chemical based products. They have the potential to improve the health and welfare of these animals and address some of the major diseases and health issues threatening pig and poultry production worldwide.
Imugene’s business model is to maximise income from the receipt of research fees, license and royalty income from an alliance partner with sufficient expertise and infrastructure to develop, market and exploit the Imugene range of vector vaccines
For more information please visit the Imugene Website www.imugene.com or contact:
| Dr Warwick Lamb | Mr Graham Dowland | Kyahn Williamson |
|---|---|---|
| Managing Director | Chairman | Investor Relations |
| Buchan Consulting | ||
| +61 2 9870 7330 | +61 8 9440 2660 | +61 (0) 40 1018 828 |
ABN 99 009 179 551
Registered Office Level 20, Allendale Square, 77 St Georges Terrace, Perth WA 6000 Tel +61 8 94402660 Fax +61 8 9 4402699
==> picture [172 x 64] intentionally omitted <==
ABN 99 009 179 551
Appendix 4D – 31 December 2010 Half-Year Report
1. Reporting Period
The current reporting period is the period ended 31 December 2010 and the previous corresponding period is for the period ended 31 December 2009.
2. Results for Announcement to the Market.
| 31 December2010 | 31 December2009 | % Change | |
|---|---|---|---|
| $ | $ | ||
| 2.1 Revenue fromordinary activities. | 1,744,294 | 206,321 | 745% Increase |
| 2.2 Profit (loss) fromordinary activities aftertax attributable tomembers. | 743,581 | (883,074) | 184% Increase |
| 2.3 Net profit (loss) forthe period attributable tomembers. | 743,581 | (883,074) | 184% Increase |
| 2.4 Amount per securityand franked amount persecurity of interimdividend. | No interim dividends have been paid or provided for duringthe period. | ||
| 2.5 Record date fordetermining entitlementsto the dividends andpayment date. | Not applicable. | ||
| 2.6 Brief explanation ofany of the figures in 2.1 to2.4 necessary to enablethe figures to beunderstood. | See Directors Report – Financial Report for the Half-YearEnded 31 December 2010. |
3. Net Tangible Assets Per Security
| 31 December2010 | 31 December2009 | |
|---|---|---|
| Cents | Cents | |
| Net tangible assets per security | 1.5 | 1.2 |
Imugene Limited Appendix 4D – 31 December 2010 Page 1
4. Gain or Loss of Control Over Entities
Not applicable.
5. Details of Dividend and Distribution Payments
No dividends or distributions have been paid or provided for during the period.
6. Dividend Reinvestment Plans
There are no dividend or distribution reinvestment plans in operation.
7. Associates and Joint Venture Entities
Not applicable.
8. Foreign Entities
Not applicable.
9. Audit Dispute or Qualification
None.
Imugene Limited Appendix 4D – 31 December 2010 Page 2